World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Research Article
ISSN: 2583-6579
SJIF Impact Factor: 5.111
Year - 2025
Volume: 4; Issue: 4
Page: 685-703

PHARMACOVIGILANCE FOR COMBINATION THERAPIES AND POLY-PHARMACY: ADDRESSING THE COMPLEXITY OF DRUG-DRUG AND DRUG-DISEASE INTERACTIONS

Apurv Santosh Khombare*, Anisha Nitin Kalolikar, Pratik Mahadev Kolhar, Shreeya Sujit Jamenis, Aryan Abhijeet Joshi, Nida Shakil Kazi

India.

Article Received: 14 July 2025 | | ***Article Revised: 04 August 2025*** | | ***Article Accepted: 25 August 2025***

Corresponding Author: Apurv Santosh Khombare
India.
DOI: https://doi.org/10.5281/zenodo.17011008

How to cite this Article: Apurv Santosh Khombare, Anisha Nitin Kalolikar, Pratik Mahadev Kolhar, Shreeya Sujit Jamenis, Aryan Abhijeet Joshi, Nida Shakil Kazi (2025). PHARMACOVIGILANCE FOR COMBINATION THERAPIES AND POLY- PHARMACY: ADDRESSING THE COMPLEXITY OF DRUG-DRUG AND DRUG-DISEASE INTERACTIONS. World Journal of Pharmaceutical Science and Research, 4(4), 685-703. https://doi.org/10.5281/zenodo.17011008

ABSTRACT

In a variety of medical specialties, including infectious diseases, oncology, and geriatrics, polypharmacy and combination therapy are growing in popularity. These methods increase the likelihood of adverse drug reactions (ADRs) even while they increase the options for treatment. It can be difficult to identify drug- disease interactions (DDSIs) and drug-drug interactions (DDIs) in post-marketing contexts since they can occur through pharmacokinetic or pharmacodynamics processes. The intricate interaction of several medications and patient comorbidities causes high-dimensional but sparse safety signals in real-world datasets, which is the source of this challenge. Modern Pharmacovigilance must combine traditional techniques—like disproportionality analysis and spontaneous reporting—with sophisticated real-world evidence analytics, mechanistic pharmacology insights, clinical decision support tools, and structured interventions like medication reviews and targeted prescribing in order to meet these challenges.

KEYWORDS: Pharmacovigilance, Drug Safety, Polypharmacy, Combination therapy, Drug- drug interactions, drug- disease interaction, etc.

INTRODUCTION

The World Health Organization (WHO) defines **polypharmacy** as the concurrent use of several medications or the use of more pharmaceuticals than are clinically required, which is an example of needless medication usage.[1] Inappropriate prescriptions, multiple drug use, or both may be involved, which could raise the risk of adverse drug events (ADEs),

underuse, or therapy duplication.[2] While inappropriate polypharmacy entails the use of drugs needlessly or harmfully without obvious therapeutic benefit, appropriate polypharmacy happens when numerous medications are provided based on clinical need to maximize outcomes and reduce damage. Polypharmacy, sometimes referred to as polytherapy or polypragmasy, has recently become a major public health problem because of the potential harm it may cause to an individual's health as well as the fact that it causes increased healthcare consumption and expenses. A recent systematic review of the definitions of polypharmacy showed that the term was most commonly applied to situations where patients took five or more medications, and this numerical definition was used by 46.4% of the studies evaluated.[1,3] While polypharmacy is often defined as routinely taking a minimum of five medicines, it is being more frequently suggested that the emphasis should be on evidenced-based practice.[4]

TYPES OF INTERACTIONS

INTERACTIONS BETWEEN DRUGS (DDIS): when the presence of one drug alters the impact of another, DDIs occur. Pharmacokinetic or pharmacodynamic interactions are the general categories for them.

Pharmacokinetic Interactions (PK): Changes in a medication's absorption, distribution, metabolism, or excretion (ADME) brought on by another drug are known as PK interactions, and they can affect systemic exposure and therapeutic results.[5]

ADME Type[6]

1. **Absorption**: Mechanisms include alterations in gastrointestinal motility, alterations in gastric pH (e.g., proton pump inhibitors decreasing absorption of ketoconazole), and chelation (e.g., tetracyclines with iron) Impact: Bioavailability may rise or fall.
2. **Distribution**: Mechanisms include competition for tissue binding sites and displacement from plasma protein binding (e.g., warfarin with valproic acid). Impact: Variations in the concentration of free drug.
3. **Metabolism**: CYP450 isoenzymes (CYP3A4, CYP2D6, and CYP2C9) are frequently involved in the mechanisms of enzyme induction or inhibition. Ritonavir, for instance, raises the plasma levels of medications like midazolam by inhibiting CYP3A4.
4. **Excretion:** Mechanisms include changes in urine pH and inhibition of renal tubular secretion (for example, probenecid lowering penicillin clearance).

Interactions in Pharmacodynamics (PD)[8]

Drugs that affect the same or comparable physiological targets can interact with one another to produce antagonistic, synergistic, or additive effects without changing pharmacokinetics. This is known as PD interaction.[7]

1. **Combined/Additive Toxicity**

   For instance, amiodarone and haloperidol, two medications that extend the QT, increase the risk of torsades de pointes when used together.
2. **Medical Synergy**

   As an illustration, β-lactam and an aminoglycoside increase the bactericidal action of bacterial endocarditis.
3. **The concept of functional antagonism**

   The effects of β-agonists, like salbutamol, and β-blockers, like propranolol, are in opposition to one another.

DRUG-DISEASE INTERACTIONS (DDSIS)[9]

- Regardless of other medications, a DDSI happens when a drug exacerbates a pre-existing medical condition and may cause harm.

- NSAIDs may cause fluid retention, which exacerbates heart failure.
- Uncontrolled diabetes mellitus may worsen as a result of corticosteroids.
- In people with asthma or chronic obstructive pulmonary disease (COPD), β-blockers may make things worse.

OTHER TYPES OF INTERACTIONS: CLINICALLY RELEVANT

1. Drug-Food Relationships(10)

- Food can affect how drugs are absorbed and metabolized.
- For instance, grapefruit juice raises simvastatin levels by inhibiting CYP3A4.

2. Interactions between Drugs and Herbs (11)

- Drug-metabolizing enzymes or transporters may be induced or inhibited by herbal supplements.
- For instance, St. John's wort reduces the efficiency of cyclosporine by inducing CYP3A4.

3. Interactions at Higher Order (12)

- When three or more medications interact, cumulative effects may result that are not apparent from single-drug interactions.
- For instance, delirium in elderly persons is caused by a number of anticholinergic medications.

COMBINANTION THERAPY

The intentional use of two or more therapeutic agents—such as medications, biologics, or a drug-device combination—to treat a single illness or condition is known as combination therapy or combination treatment. (13) These agents can be given as fixed-dose combination (FDC) formulations, concurrently, or sequentially. The strategy seeks to attack several disease pathways simultaneously, reduce the required dosage of each component, decrease or stop the emergence of resistance, and improve therapy efficacy through synergistic or additive effects.

KEY FEATURES[14]

- **Enhanced efficacy:** Produces additive or synergistic effects that are greater than what could be produced by a single drug alone HMS LINCS Project
- **Prevention of resistance:** Decreases the possibility of resistance emergence; the probability of resistant clones emerging is exponentially reduced with each additional chemical introduced
- **Multi-pathway targeting:** Acts on several molecular or cellular pathways at once to address several facets of disease biology
- **Safety and dose reduction:** Combining medications may result in lower effective doses for each, which could lessen adverse effects.

Mechanism	What It Means	Benefit
Synergy	Multiple agents amplify each other's effect	Stronger efficacy, possibly at lower doses
Resistance prevention	Simultaneous targeting of different mechanisms	Lower chance of treatment failure due to resistance
Multi-pathway targeting	Hits several disease pathways at once	More comprehensive disease control
Immune modulation	Encourages immune response to treatment	Greater tumor kill via immune system activation
Precision modalities	Uses nanotech, biomarkers, targeted approaches	Enhanced effectiveness, reduced toxicity

PROS[15]

- **Improved efficacy**: Compared to monotherapy, synergistic or additive effects may produce superior therapeutic outcomes.
- **Preventing resistance** lowers the possibility of tumor clones or resistant strains emerging.
- For more **comprehensive management**, multi-pathway targeting simultaneously affects several disease pathways.
- **Reduce the dosage** of each medicine separately to reduce dose-dependent toxicity.
- A potentially **shorter course of treatment** could hasten the attainment of therapeutic objectives.
- Options for **individualized treatment** – can be modified in accordance with the genetic or molecular profiles of individual patients.

CONS[15]

- **Increased risk of side effects**: Drug combinations can exacerbate existing toxicities or create new ones.
- Increased likelihood of **medication interactions Conflicts** involving pharmacodynamics or pharmacokinetics are more common.
- **Multiple dose** schedules associated with complex treatment regimens may **decrease patient adherence.**
- **Cost increase**: It can be costly to use multiple drugs or fixed-dose combos.
- **Monitoring difficulties**: To guarantee safety and effectiveness, regular testing and follow-ups are necessary.
- **Regulatory obstacles:** Getting novel combinations approved can be expensive and time- consuming.

SIDE EFFECTS

Aspect	Combination Therapy	Monotherapy
Overall side effect frequency[16]	Generally higher, due to additive or synergistic toxicities from multiple agents.	Typically lower, since only one drug is involved.
Type of side effects[17]	Broader spectrum — can include side effects from each component plus interaction-related effects.	Limited to those associated with the single drug used.
Severity of side effects[18]	May be more severe if overlapping toxicities occur (e.g., bone marrow suppression from two chemo drugs).	Usually less severe, unless the single drug has a high inherent toxicity.
Drug–drug interactions[19]	Higher risk — pharmacokinetic and pharmacodynamic interactions may create unexpected adverse reactions.	No drug–drug interaction risk from therapy itself.
Organ-specific toxicity[18]	Risk increases if multiple drugs affect the same organ (e.g., two hepatotoxic drugs raising liver injury risk).	Usually limited to organs affected by the single drug.
Long-term adverse effects[18]	Potentially more cumulative damage (e.g., neuropathy, kidney damage) when multiple agents contribute.	Fewer cumulative effects, unless the drug is taken long-term at high doses.
Management complexity	Requires careful monitoring, dose adjustment, and patient education to prevent serious complications.	Easier to monitor and manage.

EPIDEMIOLOGY AND TRENDS

1. **Global prevalence and magnitude**- Polypharmacy is common worldwide, however reported rates vary greatly due to differences in definitions, people investigated, and data sources. According to data from systematic reviews and meta-analyses, prevalence in adult, and particularly older, populations typically ranges between 30 and 50 percent in many settings, with significantly higher rates seen among hospitalized and long-term care patients. Across several nations, instances of hyper polypharmacy—generally defined as the use of ten or more drugs—are also becoming more widely acknowledged.[19,20]
2. **Age, setting and population gradients**- The prevalence of polypharmacy rises sharply with age, with rates substantially greater among individuals 65 and older than in younger populations. Prevalence often exceeds 30% in this category, and among the oldest-old or those with several chronic diseases, it can reach 40–50% or higher. Additionally, compared to community-based groups, rates are noticeably higher in hospitalized or institutionalized settings. Compared to the general population, some patient groups—such as those with HIV, cancer patients receiving combination therapy, and those who are frail or multimorbid—show notably higher prevalence of polypharmacy.[21,22]
3. **Geographic and regional variation-** Due to variations in prescribing practices, healthcare system configurations, population demographics, and research methodology, the frequency of polypharmacy varies greatly among geographic locations. Significant inter-country diversity is highlighted by systematic reviews, with reported rates in older persons varying from low single digits in certain studies to over 60% in others. Certain middle-income areas also exhibit noticeably high rates of polypharmacy, despite the fact that many high-income nations tend to report higher prevalence.[23,24]
4. **Temporal trends — is polypharmacy increasing?** - Numerous locations have shown a steady increase in polypharmacy and hyper polypharmacy in recent decades, according to both cross- sectional and longitudinal studies. Growing multi-morbidity, population aging, the availability of novel treatment classes that are frequently administered in combination, and the wider acceptance of multi-drug regimens based on guidelines for chronic illnesses are all contributing reasons. Prescription practices and the incidence of polypharmacy underwent brief changes in several cohorts during the COVID-19 pandemic; some research reported increases in particular locations.[25, 26]
5. **Potentially inappropriate medications (PIMs) and safety-related trends-** Several reviews show that the prevalence of potentially inappropriate medication (PIM) use is rising, especially among older persons and specific subgroups, in addition to the rising number of medications per patient. This combination, which includes additional medications and a sizable percentage of PIMs, greatly increases the risk of preventable adverse drug events (ADEs) and associated hospitalizations, making polypharmacy's safety profile even more complex.[27,28]
6. **Motivations and Factors (Epidemiologic Correlates)-** Regional prescription patterns, high levels of healthcare use (e.g., frequent hospitalizations or specialist consultations), older age, the presence and type of several chronic diseases, and socioeconomic situations all have a significant impact on the occurrence of polypharmacy. Multi-drug regimens have also become more popular as a result of clinical practice recommendations that support combination therapy, especially in cardiovascular and oncology care.[28]
7. **Implications for Research and Surveillance**- The practicality of meta-analyses is limited and comparability is hampered by differences in criteria and methodology among epidemiologic research. In order to monitor trends, a number of recent evaluations support the use of more extensive, regularly gathered data sources, such as connected

electronic health records, insurance claims, and disease registries, as well as established criteria (such as consistent thresholds and chronicity periods). In order to more precisely assess the clinical effects of increasing polypharmacy, current priorities include monitoring by disease and age, as well as evaluating drug counts and appropriateness and risk metrics (e.g., potentially inappropriate medications, interaction risks, and drug burden indices).[29,30]

8. **Therapeutic Domains with a High Frequency of Polypharmacy and Combination Therapy**- Combination therapy is especially common in the treatment of cardiovascular and metabolic diseases, infectious diseases (including HIV, TB, and increasingly complicated antibiotic regimes), and oncology. With evidence indicating increasing rates of combination approvals and increased toxicity or adverse event incidence relative to Monotherapy in multiple trials, oncology has seen a notable expansion of complex regimens comprising targeted treatments, immunotherapies, and multi-drug combos. Similarly, chronic diseases including diabetes, hypertension, and dyslipidemia often require more than one medicine, which makes them significant contributors to population-level polypharmacy.[31,32]

IMPORTANCE OF PHARMACOVIGILANCE IN POLYPHARMACY AND COMBINATION THERAPY

1. **Safeguarding Patient Safety**[33] -While polypharmacy and combination therapy are frequently clinically justified, they significantly increase the risk of adverse drug reactions (ADRs), drug-drug interactions (DDIs), and drug-disease interactions (DDSIs). ADRs rank among the top causes of hospitalizations, morbidity, and deaths worldwide. In order to prevent patient harm, early detection of these events is made possible by efficient pharmacovigilance systems. Especially in older persons, cancer patients, and people with several chronic conditions, cumulative or synergistic interactions in multi-drug regimens can exacerbate harmful consequences.

2. **Controlling the Risks of Drug-Drug and Drug-Disease Interactions**[33] - the number of possible interaction routes grows dramatically with combination therapy and polypharmacy. Pharmacovigilance is essential since it:

- Monitoring interaction signals using real-time data analytics, active surveillance, and impromptu reporting.
- identifying interactions that are clinically significant but might not show up in pre-marketing trials
- Determining the degree of an interaction in order to advise the choice of safer therapeutic alternatives or inform dosage adjustments.

3. **Promoting Combination Regimens That Are Safe and Effective**[33] - Combination therapy is frequently necessary to achieve the best results in therapeutic disciplines like cardiovascular medicine, infectious disorders, and oncology. Using pharmacovigilance guarantees

- In multi-agent regimens, the overall benefit–risk balance is still favorable.
- Emerging patterns of toxicity are quickly identified and dealt with.
- Avoiding dangerous or unsuitable medicine combinations preserves the effectiveness of treatment.

4. **Improving Clinical Decision-Making**[33] - Sturdy pharmacovigilance systems give medical professionals evidence-based knowledge about the safety of multi-drug regimens. This is especially important for

- Adjusting the course of treatment based on the pharmacogenetic profile, organ function, and comorbidities of each patient.
- Detecting and marking potentially unsuitable pharmaceuticals (PIMs) in order to improve prescribing procedures.

- Reducing the needless burden of medications by using organized de prescribing strategies where practical.

5. **Taking Care of Vulnerable Groups** [34] - Adverse drug reactions (ADRs) are more common in immune compromised populations, the elderly, people with several chronic diseases, and oncology patients on multi-agent regimens. Pharmacovigilance with a focus on these groups.

- Keeps unnecessary hospital stays at bay.
- Reduces the weakness brought on by polypharmacy.
- Improves quality of life by providing safer, more customized drug regimens.

6. **Supporting Regulatory and Policy Actions**[35]

When it comes to combination therapy and polypharmacy, strong pharmacovigilance systems

- Provide proof to back up regulatory actions, such as product removals, boxed warnings, or label changes.
- Create criteria for prescribing and clinical practice guidelines.
- Provide information for public health campaigns that try to reduce the use of unsuitable medications.

7. **Using Evidence from the Real World**[36] - In polypharmacy, real-world pharmacovigilance (PV) data are especially important because pre-approval clinical trials frequently

- Patients taking several concurrent drugs should not be included.
- Do not fully represent the variety of pharmacological combinations that are encountered in everyday practice.
- Post-marketing PV fills this gap by using patient registries, insurance claims databases, and electronic health records to track safety across a range of demographics.

8. **Recognizing and Avoiding Potential Hazards**[37] - PV takes the initiative as multi-targeted regimens, immunotherapy combos, and precision medicine grow by

- Utilizing computer learning-based predictive models with pharmacogenomic knowledge to forecast risks.
- Minimizing damage by identifying signals early before new combinations are widely used in clinical settings.
- Directing the creation of combination regimens that are safer in upcoming clinical trials.

PHARMACOVIGILANCE STRATEGIES IN POLYPHARMACY & COMBINATION THERAPY

1) **Systems of active surveillance**[38] - The foundation of pharmacovigilance is still spontaneous reporting, however polypharmacy and combination medication need for more aggressive strategies

- Cohort Event Monitoring (CEM) and Prescription Event Monitoring (PEM) monitor the results of multi-drug regimens in specific patient populations.
- Drug classes with a high risk of interactions, such as anticoagulants, antiretroviral, and anticancer medicines, are the target of Targeted Spontaneous Reporting (TSR).
- Safety monitoring is included into standard care through active registries for the management of chronic diseases.

2) **Data mining and real-world data (RWD)**[39] - Large-scale databases, electronic health records (EHRs), and insurance claims are examples of extensive health data sources that enable:

- Identification of drug-drug interactions (DDIs) and adverse drug responses (ADRs) that clinical trials could overlook.

- Quantitative assessments of benefit and risk that make use of techniques like machine learning, Bayesian modeling, and disproportionality analysis.
- Personalized risk profiling for polypharmacy according to patient attributes such as age, comorbidities, and therapeutic medication classes.

3) **CDSS, or clinical decision support systems**[40] - Electronic prescription systems that incorporate pharmacovigilance technologies allow
- Warnings in real time for possible drug-disease interactions (DDSIs), therapeutic duplication, and DDIs.
- Prescribing procedures with evidence-based prescription guidelines.
- Automatic dose modifications for organ malfunction or increased interaction risk, which reduces drug errors.

4) **Measures to Minimize Risk (RMMs)**[41] **-** Important tactics to reduce the dangers associated with polypharmacy include
- Using comprehensive deprescribing methods and conducting routine drug reviews in patient categories at high risk.
- Avoiding potentially unsuitable drugs by using patient-specific risk assessment techniques, such as the Beers Criteria and STOPP/START criteria.
- Putting in place focused training initiatives to teach medical professionals how to administer combination treatments safely.

5) **Multidisciplinary Drug Administration**[42] - Pharmacovigilance (PV) specialists, doctors, and pharmacists must work together to manage complicated medication regimens effectively
- To prevent harmful combinations and therapeutic duplication, pharmacists supervise medication reconciliation.
- Clinical experts keep an eye out for interaction-related harm in regimens tailored to a particular disease.
- In order to inform safer prescribing practices, PV teams make sure prescribers receive prompt feedback from adverse event reports.

6) **Pharmacovigilance Guided by Pharmacogenomics Information (PV)**[43]
- To determine the risk of gene–drug interactions, perform genetic testing prior to therapy (e.g., CYP2D6, CYP3A4, and TPMT).
- Predict ADR susceptibility and customize medication choices in multi-drug regimens by utilizing pharmacogenomics knowledge.

7) **Education and Involvement of Patients**[44]
- Encourage prompt reporting and teach patients how to identify ADR symptoms early.
- Utilize mobile health apps to track polypharmacy regimens and self-report ADRs.
- Encourage medication records that are kept up to date by patients in order to facilitate communication between care settings.

8) **International and Regulatory Cooperation**[45]
- Engage in international PV networks, such as FAERS, EudraVigilance, and the WHO
- Programme for International Drug Monitoring.

- Standardize PV procedures globally to identify safety concerns across borders.
- To improve signal validation for uncommon but dangerous ADRs, share databases.

9) Advanced AI and Analytical Methods[46]

- To extract ADR data from unstructured clinical documents, apply Natural Language Processing (NLP).
- Predict interaction-related adverse drug reactions (ADRs) prior to their clinical start by using machine learning approaches.
- Use network pharmacology to predict the risks of multi-drug toxicity and display drug-interaction pathways.

DRUG SAFETY MEASURES IN COMBINANTION THERAPIES[47]

- **Comprehensive pre-clinical toxicity and DDI evaluation**- before beginning first-in-human research, do in-vitro and animal studies to describe pharmacokinetic (PK) and pharmacodynamic (PD) interactions, overlapping toxicities, and organ-specific risk.
- **Reasonable clinical trial design** (PK/PD outcomes, stepwise/staggered dosage) - Employ dose- escalation techniques **t**hat evaluate interactions, phase I combination-specific PK/PD studies, and early biomarkers of toxicity, such as a Data Safety Monitoring Board (DSMB) and halting procedures.
- **For combination/combination-device products**- an integrated risk assessment and a risk management plan (RMP) Create an RMP that details known or suspected risks, pharmacovigilance efforts, and risk-reduction strategies; for drug-device combinations, apply integrated device + drug risk approaches (ICH Q9 / ISO14971 principles).
- **TDM, or therapeutic drug monitoring**- when applicable, Use consensus thresholds and customized dosage adjustments when implementing TDM for drugs with limited therapeutic indexes or when interactions significantly change exposure.
- **Strong DDI research and labeling prior to marketing**- Provide explicit interaction warnings, monitoring, and dose-adjustment instructions on product labels, and carry out official DDI studies (victim and perpetrator roles). Detective Brochures, esmoopen.com
- **Active post-marketing surveillance**- which includes close observation and signal detection To identify unexpected ADR patterns early, use active techniques (electronic health record screening, sentinel programs, rigorous monitoring cohorts) in addition to impromptu reporting.
- **Standardized data formats and superior individual case safety reporting (ICSR)** - Assure prompt, thorough ICSR reporting to regulators in accordance with ICH/ISO requirements while preserving case quality to enable accurate analysis of signals from combinations.
- **Medication reconciliation and clinical decision support**- Reduce unintentionally dangerous combinations by using EHR-based DDI alerts, pharmacist reviews, and formal drug reconciliation during transitions of care.
- **Precision dosage and pharmacogenomics**- Preemptive genotyping can help guide drug selection and dosage in cases where metabolism or toxicity is genotype-sensitive, minimizing interaction-mediated harm.
- **Informed consent, patient education, and support to adherence**- emphasize to patients the significance of adherence and prompt symptom reporting, as well as the anticipated adverse effects and interaction risks (particularly those associated with over-the-counter and herbal medications). Provide helplines and written plans. Public Health JMIR japha.org

- **Regular safety evaluations and flexible RMP revisions**- As new information becomes available, review the RMP and labeling often; update the limits, contraindications, and monitoring frequency as necessary. Employ structured signal management procedures (triage, validation, and assessment). Agency for European Medicines (EMA)
- **Engagement with regulations and lifecycle planning**- Engage regulators (FDA/EMA) early on to reach a consensus on post-marketing obligations, preclinical/clinical DDI strategy, and special measures (such REMS-type methods) for high-risk combos.

ONE-PAGE SOP – DRUG SAFETY MEASURES IN COMBINATION THERAPY[47 TO 52]

Title: Standard Operating Procedure for Drug Safety in Combination Therapy

Version: 1.0 **Effective Date:** [Insert Date]

Prepared by: [Name] **Approved by:** [Name]

1. Purpose- To outline safety protocols for the design, implementation, and monitoring of combination therapy to minimize adverse drug reactions (ADRs) and maximize patient outcomes.

2. Scope- Applicable to all clinical teams, pharmacists Researchers, and pharmacovigilance staff involved in combination therapy for any indication.

3. Responsibilities

- **Principal Investigator / Physician:** Overall safety oversight, protocol compliance.
- **Pharmacist:** Drug–drug interaction screening, medication reconciliation.
- **Research Nurse / Clinical Coordinator:** Patient education, monitoring adherence, ADR reporting.
- **Pharmacovigilance Officer:** Post-marketing surveillance, signal detection, regulatory reporting.

4. Procedure

Pre-treatment Phase

1. Conduct **pre-clinical interaction assessment** (PK/PD, toxicity studies).
2. Perform **baseline labs** and organ function tests.
3. Review **pharmacogenomics data** where applicable.
4. Screen for potential **drug–drug and drug–herbal interactions**.
5. Provide **patient counseling** on risks, adherence, and OTC/herbal avoidance.

Initiation Phase

6. Start with **lowest effective doses**, using stepwise escalation if needed.
7. Implement **Therapeutic Drug Monitoring (TDM)** for narrow therapeutic index drugs.
8. Document all **co-medications** at start.

Monitoring Phase

9. Schedule **regular follow-up labs** and clinical assessments.
10. Monitor for **specific organ toxicities** (e.g., liver enzymes, renal function, cardiac monitoring).
11. Use **EHR-based alerts** for interaction warnings.
12. Update treatment plan if ADRs or lab abnormalities occur.

Post-treatment / Lifecycle Phase

13. Conduct **end-of-treatment safety review**.
14. Report **all suspected ADRs** to regulatory bodies using ICSR standards.
15. Participate in **signal detection programs** for emerging safety issues.
16. Update **Risk Management Plan (RMP)** as new evidence arises.

6. Documentation

- Patient consent form (signed)
- Baseline and follow-up lab reports
- TDM results (if applicable)
- ADR reports and signal assessments
- Updated medication list

METHODS FOR DETECTION OF DDIS AND DDSIS[53, 54]

Method & Definition	Subtypes	Example
Spontaneous Reporting Systems (SRS): Voluntary submission of adverse drug event (ADE) reports from healthcare providers, patients, and manufacturers to national or global databases.	- Proportional Reporting Ratio (PRR)- Reporting Odds Ratio (ROR)- Multi-Item Gamma Poisson Shrinker (MGPS) for multi-drug signals	FAERS identified increased rhabdomyolysis risk from clarithromycin + statin use.
Prospective Active Surveillance: Continuous follow-up of a defined patient group during therapy to detect ADEs.	- Cohort Event Monitoring (CEM): Tracks patients from prescription date, recording all clinical events.- Prescription Event Monitoring (PEM): Uses prescription data plus follow-up questionnaires	New Zealand CEM detected increased bleeding risk with warfarin + NSAIDs combination.
Electronic Health Record (EHR) Data Mining: Use of clinical records to identify possible ADEs and drug–drug interactions by linking prescriptions, lab results, and clinical notes.	- Automated Trigger Tools (e.g., abnormal lab alerts)- Natural Language Processing (NLP) for clinical notes	EHR review flagged increased AKI risk with ACE inhibitors + diuretics + NSAIDs ("triple whammy").
Claims Database Analysis: Retrospective analysis of large insurance or billing databases to detect ADE patterns and interaction risks.	- Case–Control Studies- Cohort Studies	Medicare claims data identified hypoglycemia risk from fluoroquinolones in diabetic patients on sulfonylureas.
Targeted Spontaneous Reporting: Modified SRS approach focusing on specific drugs, interactions, or populations of interest.	- Drug-class-specific surveillance- Disease-specific surveillance	Targeted monitoring in oncology revealed higher neutropenia rates in chemotherapy + colony-stimulating factor combinations.
Patient Registries: Organized system collecting data on patients	- Disease registries- Product registries	Rheumatoid arthritis biologics registry detected higher

Method & Definition	Subtypes	Example
With a specific condition or on specific therapies over time.		Infection risk with TNF inhibitors + corticosteroids.
Data Linkage Studies: Combining multiple datasets (e.g., EHR, pharmacy records, lab data) to detect ADEs and interactions.	- Deterministic linkage- Probabilistic linkage	Linked hospital and pharmacy data revealed elevated bleeding risk from dabigatran + antiplatelets in elderly patients.
In Silico Predictive Modelling: Computer-based algorithms predicting potential drug–drug interactions and ADEs before or during market use.	- Network-based prediction models- Machine learning models	Computational modelling predicted QT prolongation risk for domperidone + clarithromycin, later confirmed in clinical data.

Advanced Analytical Approaches for Detecting DDIs and DDSIs Network-Based Pharmacovigilance[55]

This method models drugs, diseases, and adverse events as interconnected nodes in a network, with relationships represented by edges. By applying graph theory and clustering algorithms, researchers can pinpoint clusters or "hotspots" of multi-drug or drug–disease associations that might be overlooked in traditional single-drug analyses. Such networks can incorporate diverse data sources, offering visual and interpretable patterns. While effective for uncovering complex relationships, these methods demand large datasets and remain vulnerable to confounding by indication. For instance, a network analysis of FAERS data revealed a triple-drug neurotoxicity pattern involving clozapine, lithium, and valproate.

Multi-Item Disproportionality Analysis[56]

An extension of traditional disproportionality techniques, this approach evaluates combinations of two or more drugs, or drugs with diseases, to identify signals that do not emerge from individual-drug analyses. Statistical tools such as the Multi-Item Gamma Poisson Shrinker (MGPS) and the Ω shrinkage measure estimate the likelihood that a given combination is reported disproportionately. These methods leverage existing spontaneous reporting systems and adjust for random variation, but they require intensive computation and still inherit underreporting biases. For example, the Ω measure in WHO VigiBase detected a synergistic bleeding risk with concurrent warfarin and NSAID use.

Artificial Intelligence and Machine Learning[57]

AI-driven models learn patterns from large, heterogeneous datasets to forecast potential interactions and adverse events. Supervised learning methods (e.g., random forests, gradient boosting) predict risks from labeled datasets, while unsupervised methods (e.g., clustering) identify high-risk patient groups based on medication profiles. Deep learning architectures, including recurrent neural networks, can process sequential prescribing data, and natural language processing (NLP) can mine unstructured clinical notes and literature for interaction evidence. These tools excel at identifying non-linear patterns and processing vast amounts of data quickly, though they may suffer from limited interpretability and over fitting. A deep learning analysis of EHRs, for example, outperformed rule-based systems in predicting hypoglycemia risk among diabetic patients with polypharmacy.

Bayesian Networks and Probabilistic Models[58]

Bayesian networks model the conditional dependencies among drugs, diseases, and adverse events as directed acyclic graphs, enabling estimation of event probabilities under various exposure scenarios. They can incorporate prior clinical or biological knowledge and tolerate missing data relatively well. However, these models can be computationally demanding and require careful prior specification to avoid misleading associations. Bayesian analysis of FAERS data,

for example, revealed a link between methotrexate and proton-pump inhibitors that heightened the risk of myeloid suppression.

Sequence Symmetry Analysis (SSA)[59]

SSA compares the timing of adverse events before and after initiation of a potentially interacting drug within the same individual, thereby minimizing between-patient confounding. This approach works well with prescription and dispensing records, particularly for short-latency events. Its utility diminishes for long-delayed effects and depends on accurate dating of prescriptions and event onset. SSA was first applied to detect increased hospitalizations following NSAID initiation in patients already using diuretics.

Multi-Source Data Fusion[60]

This strategy integrates multiple evidence streams—such as spontaneous reports, EHRs, insurance claims, clinical trial data, published literature, and patient-reported outcomes—into a harmonized analytical framework. Common data models (e.g., OMOP CDM) enable cross-source comparisons, and "signal triangulation" strengthens confidence by requiring replication across independent datasets. While highly effective in reducing false positives and capturing signals missed by any single source, it involves complex data governance and significant computational resources. This approach has been used to validate the respiratory depression risk of concurrent opioid and benzodiazepine use.

In Silico Pharmacokinetic/Pharmacodynamic Modeling[61]

Mechanistic computer models predict interactions using detailed knowledge of drug absorption, distribution, metabolism, excretion, and pharmacodynamic effects. Physiologically based pharmacokinetic (PBPK) models simulate drug concentrations under varying disease conditions, while pharmacodynamic models estimate additive or synergistic outcomes. These techniques are valuable for assessing risks before widespread clinical exposure, though their accuracy hinges on the quality of input parameters and may fail to predict unknown mechanisms. For instance, the FDA employed PBPK models to forecast strong CYP3A4 inhibition when itraconazole is administered with certain kinase inhibitors.

CASE STUDY[62]

MULTI-SOURCE DETECTION OF OPIOID–BENZODIAZEPINE INTERACTION RISK (2021)

Overview

Concurrent use of opioids and benzodiazepines—both potent central nervous system depressants—has long been associated with an elevated risk of respiratory depression and mortality. Traditional safety alerts for this combination largely relied on isolated case reports and small observational studies. In 2021, researchers employed a multi-source, data-driven strategy to produce stronger evidence in a polypharmacy context.

Approach

A team from the Duke Clinical Research Institute analyzed three complementary data sources:

- **Spontaneous Reporting Systems (FAERS)** to generate preliminary safety signals.
- **Medicare claims data** to quantify population-level risk through adjusted hazard ratios.
- **Electronic Health Records (EHRs)** for temporal and clinical context validation.

Analytical Results

- **Signal Detection**: A substantial disproportionality signal connecting the opioid–benzodiazepine combination to respiratory depression was found using the Ω shrinkage measure.
- **Cohort Results**: Within 30 days of co-prescription, the incidence of respiratory depression increased by 3.9 times, according to a Medicare research.
- **Clinical Confirmation**: According to an EHR review, pre-existing respiratory problems or additional CNS depressants were present in more than 70% of patients.

Result and Effect

The FDA and CDC strengthened their cautions against concurrent prescription, including updating the black box label, in response to this evidence. In order to improve pharmacovigilance for intricate drug-drug interactions, the study also showed how well spontaneous reports, administrative claims, and EHRs can be integrated.

CROSS-CUTTING IMPLEMENTATION ROADMAP (HIGH LEVEL)[63, 64]

Phase 1 — Pilot (6–18 months)

- Select 2–3 sentinel ADEs/combination risks.
- Use existing bio banks + EHR/claims partners to develop and test multi-omics + clinical models.
- Establish federated analytics proof-of-concept across 3–5 sites.

Phase 2 — Scale & Validate (18–36 months)

- Expand networks, harmonize data models, and validate models in external cohorts.
- Co-develop regulatory evidentiary templates and privacy frameworks.

Phase 3 — Operationalization (36+ months)

- Integrate risk models into clinical decision support and PV workflows.
- Monitor outcomes and iterate policy/regulatory guidance.

Key stakeholders and roles

- Clinicians & pharmacists: domain expertise, clinical validation.
- Data scientists & bioinformaticians: analytics, model building.
- Regulators: guidance, evidence thresholds, enforcement.
- Healthcare systems & payers: data provision, implementation.
- Patients & communities: governance, consent, equitable representation.
- Industry: supplement data, fund studies where appropriate.

FUTURE DIRECTIONS

Integration of Multi-Omics with Pharmacovigilance[65]

The incorporation of genomics, proteomics, metabolomics, and micro biome profiles into pharmacovigilance frameworks offers the potential to predict drug–drug and drug–disease interaction risks on an individualized basis. Such integration can support precision safety monitoring tailored to each patient's biological makeup.

Global Collaboration and Data Sharing[66] developing interconnected, cross-national pharmacovigilance platforms will enable the pooling of extensive and heterogeneous datasets from multiple healthcare systems, thereby improving the timeliness and accuracy of detecting complex adverse drug events (ADEs).

Regulatory Evolution toward Multi-Drug Risk Assessment[67] Current regulatory models, which primarily focus on the safety of individual drugs, must evolve toward approaches that assess cumulative and synergistic risks arising from polypharmacy and combination therapy.

Ethical and Privacy Safeguards in Big Data Pharmacovigilance[68] Leveraging large-scale data sources—such as EHRs, insurance claims, and multi-omics datasets—for safety surveillance requires a balance between research innovation and the protection of patient privacy, ensuring ethical governance and informed consent in all stages of data use.

CONCLUSION

In managing polypharmacy and combination therapies, pharmacovigilance must evolve from a single-drug focus to a comprehensive, multi-drug safety approach. Increasingly complex treatment regimens, compounded by multiple comorbidities, heighten the likelihood of drug–drug and drug–disease interactions that often escape detection through conventional monitoring. Innovative approaches—such as network- based analyses, enhanced disproportionality techniques, and the use of real-world healthcare data—are emerging to identify these intricate interaction patterns. Yet, progress depends on regulatory flexibility, robust data-sharing frameworks, and integration of safety tools into clinical decision support systems. Bridging these gaps will improve causality assessment, enable earlier identification of safety signals, and support the development of safer, evidence-based therapeutic strategies for patients on multiple medications.

REFERENCES

1. Masnoon, Nashwa, et al. "What is polypharmacy? A systematic review of definitions." BMC geriatrics, 2017; 17(1): 230.
2. Chrischilles, Elizabeth A., et al. "Inappropriate medication use as a risk factor for self-reported adverse drug effects in older adults." Journal of the American Geriatrics Society, 2009; 57(6): 1000- 1006.
3. Pazan, Farhad, and Martin Wehling. "Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences." European geriatric medicine, 2021; 12(3): 443-452.
4. Skinner, Mary. "A literature review: polypharmacy protocol for primary care." Geriatric Nursing, 2015; 36(5): 367-371.
5. Lucas, Adam J., et al. "Estimating human ADME properties, pharmacokinetic parameters and likely clinical dose in drug discovery." Expert Opinion on Drug Discovery, 2019; 14(12): 1313-1327.
6. Palleria, Caterina, et al. "Pharmacokinetic drug-drug interaction and their implication in clinical management." Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences, 2013; 18(7): 601.
7. Niu, Jin, Robert M. Straubinger, and Donald E. Mager. "Pharmacodynamic drug–drug interactions." Clinical Pharmacology & Therapeutics, 2019; 105(6): 1395-1406.
8. Chaachouay, Noureddine. "Synergy, additive effects, and antagonism of drugs with plant bioactive compounds." Drugs and Drug Candidates, 2025; 4(1): 4.

9. van Tongeren, Justine MZ, et al. "The development of practice recommendations for drug-disease interactions by literature review and expert opinion." Frontiers in pharmacology, 2020; 11: 707.
10. Gunturu, Srinivas Guptha, and T. S. Dharmarajan. "Drug–nutrient interactions." Geriatric gastroenterology. Cham: Springer International Publishing, 2021: 381-408.
11. Izzo, Angelo A. "Herb–drug interactions: an overview of the clinical evidence." Fundamental & clinical pharmacology, 2005; 19(1): 1-16.
12. Chyou, Te-Yuan, and Prasad S. Nishtala. "Identifying frequent drug combinations associated with delirium in older adults: Application of association rules method to a case-time-control design." Pharmacoepidemiology and drug safety, 2021; 30(10): 1402-1410.
13. Malik, Manzoor Ahmad, Mohmmad Younus Wani, and Athar Adil Hashmi. "Combination therapy: Current status and future perspectives." Combination therapy against multidrug resistance, 2020: 1-38.
14. Bell, D. S. H. "Combine and conquer: advantages and disadvantages of fixed-dose combination therapy." Diabetes, Obesity and Metabolism, 2013; 15(4): 291-300.
15. Bjermer, Leif. "Evaluating combination therapies for asthma: pros, cons, and comparative benefits." Therapeutic advances in respiratory disease, 2008; 2(3): 149-161.
16. Ganga, Sreedhar, Shaik Mabu Shareef, Naser Ashraf Tadvi, and Syeda Ayesha Siddiqua. "A comparative study of efficacy and adverse effects of monotherapy with combination therapy for oral anti-diabetics in diabetes mellitus type 2 patients." National Journal of Physiology, Pharmacy and Pharmacology, 2021; 11(6): 600-605. Print. doi:10.5455/njppp.2021.11.01021202126012021
17. Bishara, Delia, Chris Kalafatis, and David Taylor. "Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents." Therapeutic advances in psychopharmacology, 2020; 10: 2045125320935306.
18. Jiang, Puen, et al. "Risk comparison of adverse reactions between gemcitabine monotherapy and gemcitabine combined with albumin-bound Paclitaxel in pancreatic cancer: insights from the FDA adverse event reporting system (FAERS) database." BMC Pharmacology and Toxicology, 2025; 26(1): 1-13.
19. Kim, Sunyoung et al. “Global and regional prevalence of polypharmacy and related factors, 1997- 2022: An umbrella review.” Archives of gerontology and geriatrics, 2024; 124: 105465. doi:10.1016/j.archger.2024.105465
20. Wang, Zeyu et al. “Prevalence of Polypharmacy in Elderly Population Worldwide: A Systematic Review and Meta-Analysis.” Pharmacoepidemiology and drug safety, 2024 33(8): e5880. doi:10.1002/pds.5880
21. Toh, Janice Jia Yun et al. “Prevalence and health outcomes of polypharmacy and hyperpolypharmacy in older adults with frailty: A systematic review and meta-analysis.” Ageing research reviews, 2023; 83: 101811. doi:10.1016/j.arr.2022.101811.
22. Zhao, Yong, et al. "Multimorbidity and polypharmacy in hospitalized older patients: a cross-sectional study." BMC geriatrics, 2023; 23(1): 423.
23. Januário, Beatriz Dias et al. “Worldwide Prevalence of Polypharmacy: A Systematic Review.” Current drug metabolism, 2023; 24(8) : 568-586. doi:10.2174/1389200224666230727093010
24. Bonanno EG, Figueiredo T, Mimoso IF, Morgado MI, Carrilho J, Midão L, Costa E. Polypharmacy Prevalence Among Older Adults Based on the Survey of Health, Ageing and Retirement in Europe: An Update. J Clin Med, 2025 Feb 17; 14(4): 1330. doi: 10.3390/jcm14041330. PMID: 40004860; PMCID: PMC11856818.
25. Wang, Xiaowen et al. “Prevalence and trends of polypharmacy in U.S. adults, 1999-2018.” Global health research

and policy, 12 Jul. 2023; 8(1): 25 doi:10.1186/s41256-023-00311-4

26. Zhang N, Sundquist J, Sundquist K, Ji J. An Increasing Trend in the Prevalence of Polypharmacy in Sweden: A Nationwide Register-Based Study. Front Pharmacol, 2020 Mar 18; 11: 326. doi: 10.3389/fphar.2020. 00326. PMID: 32265705; PMCID: PMC7103636.
27. Tian, Fangyuan et al. “Prevalence of Use of Potentially Inappropriate Medications Among Older Adults Worldwide: A Systematic Review and Meta-Analysis.” JAMA network open, 1 Aug. 2023; 6(8): e2326910., doi:10.1001/jamanetworkopen.2023.26910.
28. Zhao, Mengnan et al. “Global prevalence of polypharmacy and potentially inappropriate medication in older patients with dementia: a systematic review and meta-analysis.” Frontiers in pharmacology, 24 Aug. 2023; 14: 1221069, doi:10.3389/fphar.2023.1221069.
29. Scherkl, Camilo, et al. "Towards a prescribing monitoring system for medication safety evaluation within electronic health records: a scoping review." BMC Medical Informatics and Decision Making, 2025; 25: 244.
30. Akbarov, Artur et al. “Primary Care Medication Safety Surveillance with Integrated Primary and Secondary Care Electronic Health Records: A Cross-Sectional Study.” Drug safety, 2015; 38(7): 671-82. doi:10.1007/s40264-015-0304-x.
31. Lai, Chengcheng, et al. "Efficiency of combination therapy versus monotherapy for the treatment of infections due to carbapenem-resistant Gram-negative bacteria: a systematic review and meta- analysis." Systematic Reviews, 2024; 13(1): 309.
32. Chen, Li-Ju et al. “Systematic Review and Meta-Analysis on the Associations of Polypharmacy and Potentially Inappropriate Medication with Adverse Outcomes in Older Cancer Patients.” The journals of gerontology. Series A, Biological sciences and medical sciences, 2021; 76(6): 1044- 1052. doi:10.1093/gerona/glaa128.
33. Pirmohamed, Munir, et al. "Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients." Bmj 329.7456 (2004): 15-19.
34. Lavertu, Adam et al. “A New Era in Pharmacovigilance: Toward Real-World Data and Digital Monitoring.” Clinical pharmacology and therapeutic, 2021; 109(5): 1197-1202. doi:10.1002/cpt.2172
35. Gomase, Virendra S. "Pharmacovigilance-Technological Advancements, Recent Developments and Innovations." Current Drug Safety, 2025; 20(4): 423-449.
36. Li, Yanping et al. “Opportunities and challenges of pharmacovigilance in special populations: a narrative review of the literature.” Therapeutic advances in drug safety, 28 Sep. 2023; 14: 20420986231200746, doi:10.1177/20420986231200746
37. Algarvio, Rogério Caixinha, et al. "Artificial intelligence in pharmacovigilance: a narrative review and practical experience with an expert-defined Bayesian network tool." International Journal of Clinical Pharmacy, 2025: 1-13.
38. Shakir, S. A. W., and D. Layton. "CEM and PEM in Pharmacovigilance." Drug Safety, 2002; 25(5): 349–59. doi:10.2165/00002018-200225050-00002.
39. Harpe, S. E. "Using Real-World Data for Pharmacoepidemiology and Pharmacovigilance: The Utility of Electronic Health Records." Clinical Therapeutics, 2022; 44(2): 226–38. doi:10.1016/j.clinthera.2022.01.004.
40. Kawamoto, K., et al. "Improving Clinical Practice Using Clinical Decision Support Systems: A Systematic Review." BMJ, 2005; 330(7494): 765. doi:10.1136/bmj.38398.500764.8F.
41. O’Mahony, D., et al. "STOPP/START Criteria for Potentially Inappropriate Prescribing in Older People: Version 2." Age and Ageing, 2015; 44(2): 213–18. doi:10.1093/ageing/afu145.

42. Clyne, B., et al. "Effectiveness of a Multidisciplinary Intervention in Reducing Potentially Inappropriate Prescribing in Older Patients in Primary Care." Age and Ageing, 2015; 44(5): 722–28. doi:10.1093/ageing/afv072.
43. Relling, M. V., and W. E. Evans. "Pharmacogenomics in the Clinic." Nature, 2015; 526(7573): 343–50. doi:10.1038/nature15817.
44. van Hunsel, F., A. Passier, and K. van Grootheest. "Comparing Patients' and Healthcare Professionals' ADR Reports after Media Attention: Case Study of Rosuvastatin." Drug Safety, 2009; 32(7): 617–24. doi:10.2165/00002018-200932070-00006.
45. World Health Organization. The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products. Geneva, World Health Organization, 2002.
46. Sarker, A., et al. "Utilizing Social Media Data for Pharmacovigilance: A Review." Journal of Biomedical Informatics, 2015; 54: 202–12. doi:10.1016/j.jbi.2015.02.004.
47. Zhang, J., et al. "Drug Safety Evaluation and Pharmacovigilance Considerations for Combination Therapies in Oncology." ESMO Open, 2023; 8(4): 101533. Elsevier, doi:10.1016/j.esmoop.2023.101533.
48. "A Science-Based Methodology Framework for the Assessment of Combination Safety Risks in Clinical Trials." Drug Safety, 2023. Springer, doi:10.1007/s40290-023-00465-z.
49. European Medicines Agency. Guideline on Good Pharmacovigilance Practices (GVP) Module V: Risk Management Systems. EMA, revised 2017–2019.
50. European Medicines Agency. "Risk Management Plans." EMA, 2022–2025.
51. World Health Organization. Guidance for Pharmacovigilance: Supporting National Systems to Strengthen Detection, Assessment, Understanding, and Prevention of Adverse Effects. WHO.
52. U.S. Food and Drug Administration. Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment: Guidance for Industry. FDA, 2025.
53. Vilar, Santiago, Carol Friedman, and George Hripcsak. "Detection of Drug–Drug Interactions Through Data Mining Studies Using Clinical Sources, Scientific Literature and Social Media." Briefings in Bioinformatics, 2018; 19(5): pp. 863–877. Oxford Academic, doi:10.1093/bib/bbx010.
54. Jung, Dagyeom, and Inkyung Jung. "A Simulation-Based Comparison of Drug–Drug Interaction Signal Detection Methods." PLOS ONE, 2024; 19(4): e0300268. Public Library of Science, https://doi.org/10.1371/journal.pone.0300268.
55. Ji, Xiangmin, Guimei Cui, Chengzhen Xu, Jie Hou, Yunfei Zhang, and Yan Ren. "Combining a Pharmacological Network Model with a Bayesian Signal Detection Algorithm to Improve the Detection of Adverse Drug Events." Frontiers in Pharmacology, 3 Jan. 2022; 12: article 773135. Frontiers, https://doi.org/10.3389/fphar.2021.773135. Frontiers.
56. Muniz, Francisco, et al. "Conducting and Interpreting Disproportionality Analyses Derived from Spontaneous Report Data: Multi-Item Gamma-Poisson Shrinker and Ω Shrinkage Measures." Frontiers in Drug Safety and Regulation, 2023. Frontiers, https://doi.org/10.3389/fdsfr.2023.1323057. Frontiers
57. Shi, Mai, Aimin Yang, Eric S. H. Lau, Andrea O. Y. Luk, Raymond C. W. Ma, Alice P. S. Kong, Raymond S. M. Wong, Jones C. M. Chan, Juliana C. N. Chan, and Elaine Chow. "A Novel Electronic Health Record-Based, Machine-Learning Model to Predict Severe Hypoglycemia Leading to Hospitalizations in Older Adults with Diabetes: A Territory-Wide Cohort and Modeling Study." PLOS Medicine, 2024; 21(4): e1004369. https://doi.org/10.1371/journal.pmed.1004369.

58. Norén, Gerhard N., et al. “A Bayesian Network–Based Signal Detection Model for Pharmacovigilance: Directed Acyclic Graphs to Quantify Drug–Event Correlations.” Drug Safety, 2022; 45(7): 721–731. Springer, https://doi.org/10.1007/s40264-022-01179-1.
59. Hallas, Jesper, et al. “Sequence Symmetry Analysis in Pharmacovigilance and Pharmacoepidemiologic Studies.” European Journal of Epidemiology, 2017; 32(5): 423–432. Springer, https://doi.org/10.1007/s10654-017-0281-8. Academia
60. Santori, Andrea, and Stefano Raschetti. “Multi-Source Evidence Integration in Pharmacoepidemiology: A Signal Triangulation Approach.” Pharmacoepidemiology and Drug Safety, 2021; 30(12): 1507–1515. Wiley, https://doi.org/10.1002/pds.5304.
61. Kuepfer, Lars, et al. “PBPK Modeling of Itraconazole to Predict CYP3A4-Mediated Drug–Drug Interactions: Mechanistic Insights and Regulatory Applications.” CPT: Pharmacometrics & Systems Pharmacology, 2022; 6: 623–634. Wiley, https://doi.org/10.1002/psp4.12832.
62. Park, Tae Woo, et al. “Benzodiazepine Prescribing Patterns and Deaths from Drug Overdose among US Veterans Receiving Opioid Analgesics: Case–Cohort Study.” BMJ, 2021; 372: n90. BMJ, https://doi.org/10.1136/bmj.n90.
63. Gospel, Shara. “Digital Pharmacovigilance Implementation Roadmap.” Drug Safety and Medical Device Vigilance, 6 Apr. 2025, gospelss.wordpress.com/2025/04/06/digital-pharmacovigilance- implementation-roadmap/.
64. Smeding, Linda, et al. “Incorporating Patient Needs and Perspectives in Additional Risk Minimization Measures and Other Pharmacovigilance Deliverables — A Framework and Implementation Roadmap.” Therapeutic Innovation & Regulatory Science, 17 July 2025, Springer, https://doi.org/10.1007/s43441-025-00844-5.
65. Baião, Ana R., Zhaoxiang Cai, Rebecca C. Poulos, Phillip J. Robinson, Roger R. Reddel, Qing Zhong, Susana Vinga, and Emanuel Gonçalves. “A Technical Review of Multi-Omics Data Integration Methods: From Classical Statistical to Deep Generative Approaches.” Briefings in Bioinformatics, July 2025; 26(4): bbaf355. Oxford University Press, https://doi.org/10.1093/bib/bbaf355. Oxford Academic
66. Medipharmsolutions. “The Regulatory Updates in Pharmacovigilance: Recent Changes and Implications.” Medipharmsolutions Blog, last year, medipharmsolutions.com/blog/the-regulatory- updates-in-pharmacovigilance-recent-changes-and-implications. medipharmsolutions.com
67. Salimi, Mona. “Global Collaboration in Pharmacovigilance: A New Paradigm for Safety.” Walsh Medical Media, 2023, pp. [pages not specified]. @WalshMedical
68. Jain, Ashish, Maribel Salas, Omar Aimer, and Zahabia Adenwala. “Safeguarding Patients in the AI Era: Ethics at the Forefront of Pharmacovigilance.” Drug Safety, 2025; 48: 119–127. Springer, https://doi.org/10.1007/s40264-024-01483-9. SpringerLink.